Compare SGRY & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | ANIP |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2015 | 1999 |
| Metric | SGRY | ANIP |
|---|---|---|
| Price | $14.66 | $79.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $22.25 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.1M | 270.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.14 | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | ★ $1,145,438,000.00 | $206,547,000.00 |
| Revenue This Year | $5.09 | $21.01 |
| Revenue Next Year | $5.67 | $17.59 |
| P/E Ratio | ★ N/A | $62.06 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $11.41 | $62.61 |
| 52 Week High | $24.10 | $99.50 |
| Indicator | SGRY | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 47.45 |
| Support Level | $13.29 | $76.73 |
| Resistance Level | $14.94 | $83.66 |
| Average True Range (ATR) | 0.50 | 2.34 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 57.27 | 57.65 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.